Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danbi Lee

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
Antimicrobial Agents and Chemotherapy|March 21, 2012
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovirYoung-Suk Lim, Ji-Young Lee, Danbi Lee, et al.
International Journal of Molecular Sciences|April 28, 2023
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular CarcinomaJun Ho Ji, Sang Yun Ha, Danbi Lee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 8, 2024
The therapeutic effects of vitamin D3 administration on the embryo implantationYu-Gyeong Lee, Danbi Lee, Hwijae Cha, et al.
ACS Omega|October 5, 2020
Nonspectroscopic Migratory Cell Monitoring Method Using Retroreflective Janus MicroparticlesKa Ram Kim, Danbi Lee, Kwan Young Jeong, et al.
Journal of Hepatocellular Carcinoma|September 8, 2025
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective StudyJiwon Yang, Jihye Lim, Eun Hye Kim, et al.
American Journal of Clinical Oncology|May 29, 2019
A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular CarcinomaGi-Ae Kim, Ha Il Kim, Seheon Chang, et al.
Antimicrobial Agents and Chemotherapy|May 8, 2013
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patientsYoung-Suk Lim, Ji-Young Lee, Danbi Lee, et al.
Gut and Liver|April 20, 2023
Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting AntiviralsHyeyeon Hong, Won-Mook Choi, Danbi Lee, et al.
Clinical and Molecular Hepatology|November 20, 2023
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamideHyeyeon Hong, Won-Mook Choi, Danbi Lee, et al.
Gut and Liver|March 31, 2022
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and TreatmentJonggi Choi, Jina Park, Danbi Lee, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
Antimicrobial Agents and Chemotherapy|March 21, 2012
Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovirYoung-Suk Lim, Ji-Young Lee, Danbi Lee, et al.
International Journal of Molecular Sciences|April 28, 2023
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular CarcinomaJun Ho Ji, Sang Yun Ha, Danbi Lee, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 8, 2024
The therapeutic effects of vitamin D3 administration on the embryo implantationYu-Gyeong Lee, Danbi Lee, Hwijae Cha, et al.
ACS Omega|October 5, 2020
Nonspectroscopic Migratory Cell Monitoring Method Using Retroreflective Janus MicroparticlesKa Ram Kim, Danbi Lee, Kwan Young Jeong, et al.
Journal of Hepatocellular Carcinoma|September 8, 2025
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective StudyJiwon Yang, Jihye Lim, Eun Hye Kim, et al.
American Journal of Clinical Oncology|May 29, 2019
A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular CarcinomaGi-Ae Kim, Ha Il Kim, Seheon Chang, et al.
Antimicrobial Agents and Chemotherapy|May 8, 2013
Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patientsYoung-Suk Lim, Ji-Young Lee, Danbi Lee, et al.
Gut and Liver|April 20, 2023
Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting AntiviralsHyeyeon Hong, Won-Mook Choi, Danbi Lee, et al.
Clinical and Molecular Hepatology|November 20, 2023
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamideHyeyeon Hong, Won-Mook Choi, Danbi Lee, et al.
Gut and Liver|March 31, 2022
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and TreatmentJonggi Choi, Jina Park, Danbi Lee, et al.
Pageof 19